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Abstract
Advances in genomic technology have improved our under-
standing of the genetic events that parallel breast cancer develop-
ment. Because almost all mammary carcinomas develop in the
terminal duct lobular units of the breast, understanding the events
involved in mammary gland development make it possible to
recognize those events that, when altered, contribute to breast
neoplasia. In this review we focus on lobular carcinomas,
discussing the pathology, development, and progression of pre-
malignant lobular lesions from a genomic point of view. We
highlight studies utilizing genomic approaches and describe how
these investigations have furthered our understanding of the
complexity of premalignant breast lesions.
Introduction
Breast cancer has been hypothesized to develop through a
linear histological progression from hyperplasia and in situ
carcinoma to invasive cancer, a progression model that is
possibly similar to that described for colon cancer [1,2]. It
has been suggested that this process is accompanied by
increasing genomic instability, among other hallmarks of
cancer [3]. Recent advances in genomic technology have
improved our understanding of the accumulation of genetic
events that parallel breast cancer development; they have
also revealed the complexity of premalignant lesions. Two
major breast cancer subtypes are ductal and lobular, and the
genetics of premalignant lobular breast lesions has only
recently been explored. Findings suggest that the genomic
events identified in hyperplasias and in situ carcinomas may
be causative for the development of premalignant lesions,
thus triggering or disrupting the downstream events that lead
to disease progression [4]. In this review we focus on the
development, pathology, and progression of lobular breast
lesions, and describe our current understanding of
premalignant lesions from a genomic point of view.
An overview of mammary gland development
General structure of the mammary gland
The mammary gland is composed of an organized ductal
network. Embedded within the stroma, the branching duct
system leads from the collecting ducts via the segmental and
subsegmental ducts to the terminal duct lobular units
(TDLUs) [5]. Two cell types compose the epithelium of the
duct and lobule system, namely luminal (secretory) cells and
myoepithelial cells. The myoepithelial cell layer is found
between the luminal epithelial cell layer and the basement
membrane [5,6].
Mammary development and cancer
Almost all mammary carcinomas develop within the TDLU or
the terminal ducts that enter the lobular units. An under-
standing of the development of the TDLU is fundamental to
discerning the events that are involved in neoplastic growth.
From studies of mouse mammary development and human
mammary epithelial cells grown in three-dimensional culture,
acini structures have been recapitulated and manipulated in
order to elucidate organization and development [5,7,8].
The acini that compose the TDLU are spheroid structures
with a central lumen surrounded by a layer of polarized
epithelial cells [7]. The epithelial cells that line the acini have
polarity markers, which include (but are not limited to)
epithelial (E)-cadherin and αβ-integrins [7,9]. Blocking E-
cadherin causes selective disorganization of the luminal cells;
this relationship between tissue structure and developmental
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morphogenesis has been corroborated in mouse models (for
review [10]). The bilayered configuration of the ducts and the
acinar structure are established during TDLU development.
Following epithelial cell polarization, apoptotic signals
counter the proliferative signals produced by the cells
residing in the luminal space, allowing for hollowing of the
acini in a process known as luminal morphogenesis.
Subsequent regulation of epithelial cell size, number, and
survival maintains this structure [11].
Molecular factors important to the
development of premalignant breast lesions
Pathways implicated in luminal morphogenesis
Specific pathways have been implicated in the development of
the structures that comprise the mammary gland. The above
mentioned process of luminal morphogenesis [7] is one
example. In vitro studies using three-dimensional cultures have
identified that proper formation of the hollow bilayered acinar
structure at the end of a terminal duct involves the initiation of
proliferative and apoptotic signals, leading to the formation of
the lumen. In particular, the cells located in the center of the
luminal space have been reported to lack AKT pathway signals
[11,12]. A lack of AKT survival signals would allow for selective
cell death, which, in the case of luminal morphogenesis,
contributes to the formation of the hollow lumen.
It is clear that the proliferative and apoptotic signals funda-
mental to luminal morphogenesis exist in a delicate balance.
Further evidence for this involves colony-stimulating factor
(CSF)1 receptor, a protein tyrosine kinase transmembrane
receptor that, when activated by its ligand CSF1, signals
through Ras, allowing for cell growth and differentiation.
Studies using three-dimensional mammary culture models
have reported that constitutive CSF1 receptor signaling
causes uncontrolled proliferation and altered E-cadherin
mediated adhesion, thereby disrupting normal mammary
structure and development [13]. Interestingly, loss of E-
cadherin expression is also a significant feature of lobular
carcinomas [14,15].
In general, these studies provide additional evidence that
altering the balance of proliferative and apoptotic signals can
lead to the accumulation of cells within the luminal space of
the acini [12], which is a characteristic of neoplastic breast
lesions. However, not all of the players that are involved in
luminal morphogenesis have yet been identified. Continued
research in this area will further expand our understanding of
this essential developmental process in the mammary gland.
Mammary gland microenvironment
The microenvironment and/or adjacent cells may also
contribute to the development of premalignant breast lesions.
The stroma within the mammary gland is composed of
adipocytes, fibroblasts, inflammatory cells, blood vessels, and
extracellular matrix. These components contribute instructive
and permissive signals during development. Many stromal
factors that are essential to mammary gland development
have also been found to be associated with cancer. For
example, the interaction between the epithelium and the
extracellular matrix promotes branching morphogenesis
during normal mammary development [16]. Transforming
growth factor-β, a key player in tumorigenesis, is a stromal
factor that functions to prevent inappropriate branching. If
transforming growth factor-β signaling is inhibited, excess
ductal branching results [17]. Thus, as this example
suggests, although the epithelium is responsible for
proliferation, invasion, and tumorigenic potential, the micro-
environment within which premalignant lesions develop can
play an important role.
Pathology of lobular breast lesions
Histological description
Lobular neoplasia represents a broad range of noninvasive (in
situ) proliferations of ‘lobular cells’ in the breast. These
lesions share the distinctive cytology of invasive lobular cells
and an almost exclusive distribution within the acini of a
TDLU; such characteristics give these lesions a signature
histologic appearance.
The classic cells of lobular neoplasia are small and round,
with uniform bland nuclei [18]. The nuclei are often central
but can be paracentral with an occasional cytoplasmic
vacuole, representing an invagination of the cell membrane as
evidenced by electron microscopy [19]. The loss of E-
cadherin in lobular cells imparts the discohesive quality
apparent on microscopic sections and reflects a charac-
teristic pattern of pagetoid spread and diffuse invasion
[20,21]. Although morphologically distinct, lobular neoplasia
is quite varied in terms of the extent of disease both within the
TDLUs and within the breast in general, and as such is
classified into significant clinical entities (as verified by follow
up). These classifications include minimal atypical lobular
hyperplasia (MALH), atypical lobular hyperplasia (ALH), with
or without ductal involvement by cells of ALH (DIALH), lobular
carcinoma in situ (LCIS), and invasive lobular carcinoma (ILC;
Figure 1)
Most lobular lesions are classified as ALH, which is defined
as the expansion of a lobular unit with a uniform population of
cells. In a TDLU, evident expansion of at least one acinar
space, with a minimum of eight cells across, is mandatory for
the diagnosis of ALH [22]. The designation MALH is
appropriate in cases in which the lobular unit is populated by
cells of ALH with minimal to no expansion of the acini (four to
five cells across an acinar diameter). The distinction between
ALH and MALH is important because MALH represents a
significantly lower risk for subsequent development of
invasive carcinoma than does classic ALH. Regressed ALH is
a pattern of ALH that may be identified in postmenopausal
women in which the ALH lesion is less developed; has a
more varied and scant population of lobular cells with
degenerating changes, as compared with classical examples;Page 3 of 9
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and may lack the minimum criteria for diagnosis (Page DL,
personal communication; Figure 2a). These morphologic
characteristics may prove to be related to the lower
associated cancer risk reported in postmenopausal women
diagnosed with ALH.
DIALH describes the pattern of pagetoid spread that cells of
ALH exhibit when traveling down ducts, undermining the
normal ductal epithelium. This lesion is usually observed in
association with ALH or LCIS [23]. Moreover, LCIS repre-
sents the higher spectrum of ALH, with marked distention
and distortion of more than 50% of acini within a lobular unit,
and may be designated tumor forming when clustered
(Figure 2b).
Breast cancer risk
The clinical implications for cancer vary between the different
subtypes of lobular neoplasia. Diagnostic ALH has been
shown to be a general indicator for bilateral cancer risk, with
a fourfold to fivefold increase in relative risk compared with
the general population [22,24-26]. It should be noted that
although ALH may be linked to increased risk in both breasts,
a recent study has shown that the ipsilateral breast
(compared with the contralateral breast) is somewhat more
likely to develop subsequent invasive disease [25,27].
Cancer risk in ALH also appears to vary with patient age; an
initial diagnosis of ALH in women older than 55 years
(postmenopausal) has been linked to a lower associated
cancer risk, which is not true of lesions in younger premeno-
pausal women [25,27]. Interestingly, it is in the lesions found
in postmenopausal women that we observe regressed ALH
(see above). Taken together, these factors suggest that
regressed ALH may have morphologic characteristics, and
possibly a genomic signature, that distinguish it from classic
ALH.
Lesions that exhibit sufficient distention and distortion for the
diagnosis of LCIS have been found to carry an associated
breast cancer risk twice that of ALH [28,29]. Although DIALH
was initially believed to increase risk similarly to LCIS [23], a
more recent study involving a longer period of follow up
reported that this increased risk was not statistically
significant [27].
Lobular verses ductal lesions
Compared with lobular lesions, atypical ductal hyperplasia
and ductal carcinoma in situ (DCIS) exhibit varied patterns,
including solid, cribriform, and micropapillary. In terms of risk,
Available online http://breast-cancer-research.com/content/9/6/215
Figure 1
Lobular neoplasia. The classification of lobular neoplasia is determined by the extent of disease both within the terminal duct lobular units and
within the breast in general. The clinical entities that fall into the classification of lobular neoplasia include (a) minimal atypical lobular hyperplasia
(magnification: 200×), (b) atypical lobular hyperplasia (ALH; 200×), (c) ALH with ductal involvement by cells of ALH (200×), (d) lobular carcinoma
in situ (100×), and (e) invasive lobular carcinoma (200×). All lesions were stained with hematoxylin and eosin.atypical ductal hyperplasia appears to carry a slightly lower
generalized increased cancer risk than does ALH, with a
relative risk of about three to four times that in the general
population [24,25]. DCIS is a localized premalignant lesion
and, if not excised, is highly likely to progress locally to
invasive carcinoma.
Pathologic indications for progression
Lobular neoplasia is a definitive risk indicator for the develop-
ment of breast cancer. This association was first demon-
strated by Foote and Stewart in 1941 [30], with a report that
described the co-occurrence of LCIS and ILC in 60% of
cases in their study. These seminal findings began the
investigations into the evolution of lobular neoplasia and were
recently reproduced by Bratthauer and Tavassoli [31], who
reported a 23% coincident incidence of invasive cancer in
association with LCIS, with 86% of the invasive tumors being
ILC. This evidence is quite compelling but the association
remains morphologic and the capacity to predict progression
is limited. However, underlying genomic alterations, as
discussed in the following sections, may significantly enhance
our ability to predict neoplastic behavior.
The genomic point of view
In the past, loss of heterozygosity (LOH) [32], fluorescence in
situ hybridization [33], and chromosomal comparative geno-
mic hybridization (CGH) [34] were techniques used to
identify the genetic alterations underlying solid human neo-
plasms. More recently, however, there has been an increasing
use of array-CGH [35], a high-throughput technique for the
high-resolution detection of copy number alterations at a
genome-wide level.
Whereas chromosomal-CGH allows for the identification of
regions of DNA gain/loss of more than 20 megabases
throughout the genome by hybridization of a sample to
metaphase chromosomes immobilized on a glass slide [34],
array-CGH has the same theoretical end-point but with a
refined process and resolution. Most recently, using a
genomic DNA template and tiling bacterial artificial
chromosome (BAC) microarray, copy number alterations can
be identified at the submegabase level [36]. Array-CGH can
be manipulated to evaluate the genome of any cell and has
been applied to the identification and differentiation of breast
cancers [37,38].
Array-CGH data has been proven to complement gene
expression data obtained from cDNA microarrays [37,39,40].
Coupling the gain/loss of chromosomal regions with the
increase/decrease of gene expression has identified
significantly altered genes that are putative mediators of
tumor formation or progression.
Genomics and premalignant lobular breast
lesions
Genomic alterations in lobular neoplasia
Molecular studies of ALH are sparse, limited by the small size
and rarity of these lesions. To date, only two studies have
investigated ALH for genomic alterations. Lu and colleagues
[41] examined ALH (and LCIS) lesions, as well as the
associated invasive breast cancers, using chromosomal-
CGH and identified alterations at chromosomes 6, 16, 17,
and 22. These alterations were found at similar frequencies in
ALH and LCIS. Based on the CGH profiles and the average
number of genomic alterations found in both types of lesion
(2.9 in both), those investigators suggested that ALH and
LCIS represent the same genetic stage of development.
More recently, Mastracci and coworkers [4] profiled solitary
ALH lesions using a whole-genome tiling BAC-array. This
Breast Cancer Research    Vol 9 No 6 Mastracci et al.
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Figure 2
Suggested new entities of lobular neoplasia. (a) Regressed atypical lobular hyperplasia (ALH; magnification 200×) is a pattern of ALH present in
postmenopausal women, in which the ALH lesion is less developed; has a more varied population of lobular cells than classical ALH, with the
presence of apoptotic bodies; and meets the minimum criteria for diagnosis. (b) Tumor-forming lobular carcinoma in situ (LCIS; 20×) is defined by
clustering of LCIS in at least two adjacent lobular units, and may have specific implications for cancer risk and required excision. Lesions were
stained with hematoxylin and eosin.study represents the most in-depth investigation of the ALH
genome. The reported genomic signature identified and
further refined the alterations reported by Lu and colleagues
[41]. Novel regions of copy number gain and loss, including
gain at 2p11.2 and loss at 7p11-p11.1 and 22q11.1, were
determined to be common to ALH. In this study, the authors
also investigated solitary LCIS [4]. Novel regions of copy
number alteration were found to be common to LCIS,
including gain at 20q13.13 and loss at 19q13.2-q13.31. In
both ALH and LCIS the region of loss at 16q21-q23.1 was
identified to be altered. Furthermore, genes within regions of
alteration common to both ALH and LCIS were identified to
be involved in the process of luminal morphogenesis.
To date, no studies have investigated genomic alterations in
MALH or DIALH. Three studies have analyzed LCIS with
adjacent invasive carcinoma using array-CGH platforms.
Shelley Hwang and coworkers [42] evaluated 24 synchro-
nous LCIS and ILC lesions and found alterations of 16q loss,
1q gain, 11q14-11qter loss, and 11q11-q13 loss. Moreover,
in their case report, Nyante and colleagues [43] evaluated
three synchronous lesions, including DCIS, LCIS, and ILC.
They detected two different genomic signatures. The LCIS
and ILC were found to harbor loss at 1p, 16q, and 17p/q,
whereas the DCIS exhibited loss at 6q and 11q and gain at
10p, 11q, and 15q. The third study, that reported by Morandi
and coworkers [44], investigated the clonality of synchronous
lobular neoplasia and ILC. They identified common regions of
alteration, including gain at 19p, 6p, 1p, 3p, 16p, 21q and
2q, and loss at 16q and 19q. From this study lobular
neoplastic lesions were reported to be genetically related to
ILC and consequently categorized as precursors.
Alterations found in invasive lobular carcinomas
Loss of 16q is one of the most frequent events found in
breast cancer and appears to be the most consistent
alteration found in ILC by both chromosomal-CGH and array-
CGH. Chromosomal-CGH studies identified a myriad of
alterations, but these reports only agree that lobular
carcinomas have a recurrent loss of 16q (where the
E-cadherin gene [CDH1] is located), a frequent gain of 1q,
and are different from invasive ductal carcinomas (IDCs)
[45-49]. These particular genomic alterations were again
recently identified in a study of classic lobular carcinomas,
which employed both high-resolution CGH and array-CGH
[50]. Moreover, an array-CGH study conducted by Roylance
and colleagues [51] identified that ILC and low-grade IDC
exhibit loss of the whole arm of 16q, whereas high-grade IDC
shows regional gain and loss on 16q but infrequent whole-
arm loss. However, despite the studies distinguishing lobular
from ductal carcinomas, and notwithstanding the advance-
ments in high-throughput technology, there is currently no
accepted genomic signature specific for ILC.
A comprehensive list of the alterations identified to date in
lobular carcinomas is presented in Table 1.
Are we closer to understanding the
development of premalignant lobular breast
lesions?
Cases containing ALH and/or LCIS without adjacent invasive
carcinomas are known to occur in only 0.5% to 3.8% of
breast cases that are otherwise benign. Despite their rarity,
these cases spark intrigue with respect to progression.
Epidemiologic studies have not provided concrete evidence
for progression, but rather have deemed these lesions to be
risk indicators. From a molecular perspective, the cells that
characterize premalignant lesions may not have acquired all
of the ‘hallmarks’ of cancer cells. Those properties relating to
the development of the normal mammary gland are potential
candidates for malfunction in the cells that define pre-
malignant breast lesions.
Specific clues to the development of lobular neoplastic lesions
have only recently been described. Unbalanced proliferative
and apoptotic signals that contribute to altered luminal
morphogenesis may provide biologic cues that initiate lobular
neoplastic proliferation. Genomic alterations, described by
array-CGH, in regions that contain genes involved in luminal
morphogenesis provided the first evidence for the link
between these clinical entities and the developmental process
[4]. One example is AKT1, a gene identified to be altered at
the 14q32.33 locus in both ALH and LCIS (Figure 3). A lack
of AKT pathway survival signals is characteristic of the cells
located in the lumen of the acinar structure during the process
of luminal morphogenesis. An increase in the amount of AKT1
would provide the pro-proliferative signals necessary for the
survival and proliferation of these cells.
Do certain genomic alterations give clues to
progression?
Synchronous lesions of LCIS and ILC appear to have a high
degree of similarity. Molecular studies investigating these
lesions for LOH [52], protein expression of the E-cadherin
adhesion complex [15], and mutations in CDH1 and LOH at
16q [14] suggest a relationship between adjacent lesions. As
outlined in the preceding section, recent array-CGH studies
have also reported similarities in the genomic alterations
identified in adjacent lobular lesions.
From a molecular point of view it has been suggested that
ALH and LCIS are nonobligate precursor lesions. Thus, for
progression to ensue, these solitary lobular neoplastic lesions
would require additional molecular or genetic events to take
place. Interestingly, a recent study conducted in a mouse
mammary tumor model investigated the somatic loss of E-
cadherin [53]. This study provided evidence that loss of E-
cadherin in a p53-deficient background plays a role in the
initiation, progression, and metastasis of mammary carcinomas.
In particular, these mice developed tumors that appeared
strikingly similar to human ILC, with evidence of anoikis
resistance, angiogenesis, and acquired potential for stromal
invasion. Thus, in premalignant lobular lesions the detection
Available online http://breast-cancer-research.com/content/9/6/215
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Table 1
Published reports of genomic alterations identified by comparative genomic hybridization in lobular carcinoma
Cases studied Noted lobular-specific alterations
Reference ALH/LCIS Invasive Other Type of CGH Gain Loss Observations
Lu and  ALH and  IBC (adjacent  Chromosomal 6q 16p, 16q,  Alterations were found at a 
coworkers [41] LCIS in 6 cases) 17p, and  similar high frequency in LCIS 
22q and ALH
Buerger and  LCIS ILC (adjacent  DCIS Chromosomal 1q 16q LCIS characterized by low 
coworkers [45] LCIS in  average rate of copy number 
4 cases) changes; no evidence of 
amplification in LCIS
Gunther and  ILC and IDC Chromosomal 16q, 17q,  Lower frequency of gain at 8q in 
coworkers [46] and 22 ILC compared with IDC; changes 
of equal frequency include gain at 
1q, and loss at 19p and parts of 
1p and 11q
Weber-Mangal  ILC and IDC  IBC Chromosomal 1q, 8q, and  16q, 17p,  Lobular alterations were identified 
and coworkers  11q and 22q in a table of alterations; however, 
[47] the study investigated alterations 
in breast cancer in general
Nishizaki and  ILC and IDC Chromosomal 1q 16q Compared ILC with IDC; IDC had 
coworkers [48] higher frequency of gain at 8q 
and 20q
Etzell and  LCIS Chromosomal 1q 8p, 12q24,  Correlated 16q loss with loss of 
coworkers [49] 16q, and  expression of E-cadherin by 
17p immunohistochemistry
Mastracci and  ALH and  SMRT  2p11.2 and  7p11.2,  Alterations found in common 
coworkers [4] LCIS BAC-array 20q13.13 16q21-q23.1,  between ALH and LCIS; also 
19q13.2, and  identified changes that were 
22q11.1 specific to either ALH or LCIS
Loo and  ILC  IDC BAC-array 1q32, 8p23,  16q23 and  Found differences between ILC 
coworkers [38] 11q13, and  16q24 and IDC, stratified by histologic 
11q14 type and estrogen receptor status
Hwang and  LCIS ILC  BAC-array 1q 11q11-q13,  Clonality was suggested for the 
coworkers [42] (synchronous) 11q14-qter,  genetic relationship between 
and 16q LCIS and ILC
Nyante and  LCIS ILC  DCIS BAC-array 1p, 16q, and  A different profile was identified 
coworkers [43] 17p/q for DCIS
Morandi and  ILC Oligo-array 1p, 2q, 3p,  16q and 19q Lobular neoplastic lesions are 
coworkers [44] 6p, 16p, 19p,  genetically related to ILC and can 
and 21q be categorized as precursors
Reis-Filho and  ILC High-resolution  1q, 5p, 7q,  11q, 13q, 16q,  Lobular carcinomas have greater 
coworkers [50] CGH and  11p, 11q, 12q,  18q, and Xq genetic complexity and a higher 
array-CGH 14q, 16p, 18p,  number of recurrent genomic 
19p+q, and  changes than previously reported 
20p+q with other techniques
Roylance and ILC and IDC 16q  16q (whole  Alterations on 16q are common to 
coworkers [51] BAC-array chromosome  both IDC and ILC; higher grade 
arm) IDCs have more complex changes 
on 16q
The ‘cases studied’ column notes the breast lesion investigated in each study, i.e. ALH/LCIS, Invasive carcinoma or other breast lesions. The
‘noted lobular-specific alterations’ column notes the chromosomal gains and losses identified in each study. ALH, atypical lobular hyperplasia;
BAC, bacterial artificial chromosome; DCIS, ductal carcinoma in situ; IBC, invasive breast cancer; IDC, invasive ductal carcinoma; ILC, invasive
lobular carcinoma; LCIS, lobular carcinoma in situ; LN, lobular neoplasia; SMRT, submegabase resolution tiling array.of loss of 16q (the locus that harbors the E-cadherin gene)
might point to possible progression toward an invasive
phenotype, given the frequency of this alteration in invasive
breast cancer and the functional effect of loss of CDH1.
Additional chromosomal alterations, including loss at 1p, 11q
and 17p/q, and gain at 1q, identified in synchronous lobular
lesions may also contribute to progression [41-43]. The
presence of these alterations in both the invasive and
adjacent premalignant lesions suggests that genes within
these altered regions may alter the proliferation program or
affect cell death, thereby contributing to and/or maintaining
the invasive properties of these cells. In general, alterations
identified in adjacent in situ and invasive lobular lesions could
provide a selective advantage during tumor initiation, thereby
encouraging tumor development and progression.
Is there genomic evidence to support lobular
breast cancer progression?
Compelling evidence for progression has yet to be reported.
Advances in the resolution of array-CGH technology allow
specific identification of genomic breakpoints. As such,
studies identifying identical genomic breakpoints in solitary
lobular neoplastic lesions and solitary ILC would provide
strong support for progression from premalignant to invasive
disease. Loss at 16q and gain at 1q have been suggested to
be frequent events linked to progression, but identical
breakpoints within these, or novel loci, would provide direct
evidence linking genomic alterations to breast cancer
progression.
Conclusion
Recent advances in genomic technology have provided new
tools for in-depth, fine-scale mapping of genomes, allowing
successful study of small premalignant breast lesions at the
genome level. An understanding of the events that are
involved in mammary gland development makes it possible to
recognize those events that, when altered, contribute to
breast neoplasia. However, recent genomic studies have only
begun to uncover clues to neoplastic development in the
breast. Definitive proof of the progression to invasive disease
will require the discovery of identical breakpoints in adjacent
lesions using array-CGH technology. Continued evolution of
the technology and further investigation will contribute to a
better understanding of the pathways and processes that are
involved in the development and progression of lobular breast
cancer.
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Figure 3
Genomic techniques. Genomic techniques can identify alterations that are fundamental and possibly functionally significant to development of
premalignant breast lesions. (a) An example of a gain on chromosome 14 is illustrated in this ideogram (data from Mastracci and coworkers [4]).
The specific region of gain at 14q32.33 (highlighted in blue) was identified in atypical lobular hyperplasia and lobular carcinoma in situ. (b) The
region of gain at 14q32.33 magnified and showing the genes encompassed by the amplified bacterial artificial chromosomes. AKT1 has been
implicated in the process of luminal morphogenesis, and a copy number gain of the region containing AKT1 could produce the reported effect on
this developmental process.Acknowledgements
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